Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

NCT ID: NCT01586195

Last Updated: 2017-05-25

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 31 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-10-31
• Study Completion Date: 2015-04-30

Brief Summary

This is an open-label, multicenter, single-agent, phase II study of continuous oral Zelboraf (vemurafenib) in participants with locally-advanced, unresectable, stage IIIc or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.

Conditions

Malignant Melanoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Vemurafenib

Participants with untreated or previously treated locally advanced, unresectable, Stage IIIc or metastatic melanoma who have an activating exon 15 BRAF mutation other than V600E received vemurafenib 960 milligram (mg) orally twice daily (BID) until disease progression.

Group Type: EXPERIMENTAL

Vemurafenib

Intervention Type: DRUG

Vemurafenib 960 mg BID

Interventions

Vemurafenib

Vemurafenib 960 mg BID

Intervention Type: DRUG

Other Intervention Names

Zelboraf

Eligibility Criteria

Inclusion Criteria

• Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
• Histologically-confirmed metastatic melanoma (unresectable Stage IIIc or IV) with an activating BRAF mutation other than V600E, as detected by DNA sequencing of exon 15 performed at a centralized laboratory
• Measurable disease (as defined by RECIST, v1.1)
• Adequate recovery from most recent systemic or local treatment for cancer
• Adequate organ function within 28 days prior to initiation of treatment
• For women of childbearing potential, agreement to the use of two acceptable methods of contraception, including one barrier method, during the study and for 6 months after discontinuation of vemurafenib
• For men with female partners of childbearing potential, agreement to use a latex condom and to advise their female partner to use an additional method of contraception during the study and for 6 months after discontinuation of vemurafenib
• Negative serum pregnancy test within 7 days of commencement of treatment in premenopausal women. Women who are either surgically sterile or have been post-menopausal for at least 1 year are eligible to participate in this study
• Agreement not to donate blood or blood products during the study and for at least 6 months after discontinuation of vemurafenib; for male participants, agreement not to donate sperm during the study and for at least 6 months after discontinuation of vemurafenib
• Signed informed consent form (prior to study entry and before performing any study-related procedures)

Exclusion Criteria

• Invasive malignancy other than melanoma at the time of enrollment and within 2 years prior to first study drug administration, except for adequately treated (with curative intent) basal or squamous cell carcinoma, in situ carcinoma of the cervix, in situ ductal adenocarcinoma of the breast, in situ prostate cancer, or limited stage bladder cancer or other cancers from which the patient has been disease-free for at least 2 years
• Pregnant or breast-feeding
• Inability to swallow pills
• Concurrent anti-tumor therapy (e.g., chemotherapy, other targeted therapy, radiation therapy, including participation in an experimental drug study)
• Radiation therapy </= 1 week prior to first administration of vemurafenib and stereotactic radiotherapy </= 1 day prior to first administration of vemurafenib
• Prior treatment with a BRAF or MEK inhibitor
• Either a concurrent condition (including medical illness, such as active infection requiring treatment with IV antibiotics or the presence of laboratory abnormalities) or history of a prior condition that places the patient at unacceptable risk if he/she were treated with the study drug or confounds the ability to interpret data from the study
• History of congenital long QT syndrome or a corrected QT (QTc) interval > 450 ms at baseline
• Ongoing cardiac dysrhythmia >/= Grade 2
• Unwillingness to practice effective birth control
• Inability to comply with other requirements of the protocol

• Minimum Eligible Age: 16 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Genentech, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clinical Trials

Role: STUDY_DIRECTOR

Genentech, Inc.

Locations

Arizona Cancer Center

Tucson, Arizona, United States

UCSD Moores Cancer Center

La Jolla, California, United States

UCLA School of Medicine; Hematology/Oncology

Los Angeles, California, United States

The Angeles Clinic and Research Institute, Santa Monica Office

Santa Monica, California, United States

University of Colorado; Anschutz Cancer Pavilion

Aurora, Colorado, United States

Moffitt Cancer Center

Tampa, Florida, United States

Emory University; Winship Cancer Institute

Atlanta, Georgia, United States

Oncology Specialists, S.C.

Park Ridge, Illinois, United States

Washington University School of Medicine

St Louis, Missouri, United States

Atlantic Health System

Morristown, New Jersey, United States

Columbia University Medical Center

New York, New York, United States

Mid Ohio Onc Hematology Inc

Columbus, Ohio, United States

UPCI Cancer Institute; Cancer Pavillion

Pittsburgh, Pennsylvania, United States

Vanderbilt Univ Medical Ctr

Nashville, Tennessee, United States

Texas Oncology-Baylor Sammons Cancer Center

Dallas, Texas, United States

Countries

United States

Other Identifiers

ML27763

Identifier Type: -

Identifier Source: org_study_id